YAP/TAZ: a promising target for squamous cell carcinoma treatment

References

• Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–920. doi:10.1038/ncb105014502294
   PubMed Web of Science ®Google Scholar
• Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122(3):421–434. doi:10.1016/j.cell.2005.06.00716096061
   PubMed Web of Science ®Google Scholar
• Kanai F, Marignani PA, Sarbassova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. Embo J. 2000;19(24):6778–6791. doi:10.1093/emboj/19.24.677811118213
   PubMed Web of Science ®Google Scholar
• Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev. 2013;27(4):355–371. doi:10.1101/gad.210773.11223431053
   PubMed Web of Science ®Google Scholar
• Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9(5):534–546. doi:10.1101/gad.9.5.5347698644
   PubMed Web of Science ®Google Scholar
• Kango-Singh M. Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development. 2002;129(24):5719–5730.12421711
   PubMed Web of Science ®Google Scholar
• Tapon N, Harvey KF, Bell DW, et al. salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002;110(4):467–478.12202036
   PubMed Web of Science ®Google Scholar
• Harvey KF, Pfleger CM, Hariharan IK. The drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457–467.12941274
   PubMed Web of Science ®Google Scholar
• Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in drosophila. Nat Cell Biol. 2003;5(10):921–927. doi:10.1038/ncb105114502295
   PubMed Web of Science ®Google Scholar
• Wu S, Huang J, Dong J, Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and warts. Cell. 2003;114(4):445–456.12941273
   PubMed Web of Science ®Google Scholar
• Lai ZC, Wei X, Shimizu T, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005;120(5):675–685. doi:10.1016/j.cell.2004.12.03615766530
   PubMed Web of Science ®Google Scholar
• Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J. The TEAD/TEF family of transcription factor scalloped mediates Hippo signaling in organ size control. Dev Cell. 2008;14(3):377–387. doi:10.1016/j.devcel.2008.01.00618258485
   PubMed Web of Science ®Google Scholar
• Guo T, Lu Y, Li P, et al. A novel partner of scalloped regulates Hippo signaling via antagonizing scalloped-yorkie activity. Cell Res. 2013;23(10):1201–1214. doi:10.1038/cr.2013.12023999857
   PubMed Web of Science ®Google Scholar
• Thompson BJ, Cohen SM. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in drosophila. Cell. 2006;126(4):767–774. doi:10.1016/j.cell.2006.07.01316923395
   PubMed Web of Science ®Google Scholar
• Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994;9(8):2145–2152.8035999
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811–828. doi:10.1016/j.cell.2015.10.04426544935
   PubMed Web of Science ®Google Scholar
• Fu V, Plouffe SW, Guan KL. The Hippo pathway in organ development, homeostasis, and regeneration. Curr Opin Cell Biol. 2017;49:99–107. doi:10.1016/j.ceb.2017.12.01229316535
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287–1312. doi:10.1152/physrev.00005.201425287865
   PubMed Web of Science ®Google Scholar
• Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877–883. doi:10.1038/ncb230321808241
   PubMed Web of Science ®Google Scholar
• Hong AW, Meng Z, Guan KL. The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol. 2016;13(6):324–337. doi:10.1038/nrgastro.2016.5927147489
   PubMed Web of Science ®Google Scholar
• Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076–2086. doi:10.1038/sj.onc.120844515688006
   PubMed Web of Science ®Google Scholar
• Hwang E, Ryu KS, Paakkonen K, et al. Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. Proc Natl Acad Sci U S A. 2007;104(22):9236–9241. doi:10.1073/pnas.061071610417517604
   PubMed Web of Science ®Google Scholar
• Ni L, Zheng Y, Hara M, Pan D, Luo X. Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling. Genes Dev. 2015;29(13):1416–1431. doi:10.1101/gad.264929.11526108669
   PubMed Web of Science ®Google Scholar
• Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283(9):5496–5509. doi:10.1074/jbc.M70903720018158288
   PubMed Web of Science ®Google Scholar
• Schumacher B, Skwarczynska M, Rose R, Ottmann C. Structure of a 14-3-3sigma-YAP phosphopeptide complex at 1.15 A resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66(Pt 9):978–984. doi:10.1107/S1744309110025479
   PubMedGoogle Scholar
• Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010;24(1):72–85. doi:10.1101/gad.184381020048001
   PubMed Web of Science ®Google Scholar
• Guo L, Teng L. YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol. 2015;46(4):1444–1452. doi:10.3892/ijo.2015.287725652178
   PubMed Web of Science ®Google Scholar
• Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–1971. doi:10.1101/gad.166440818579750
   PubMed Web of Science ®Google Scholar
• Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28(7):2426–2436. doi:10.1128/MCB.01874-0718227151
   PubMed Web of Science ®Google Scholar
• Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012;109(37):E2441–50. doi:10.1073/pnas.121202110922891335
   PubMed Web of Science ®Google Scholar
• Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 2003;278(35):33334–33341. doi:10.1074/jbc.M30559720012807903
   PubMed Web of Science ®Google Scholar
• Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A. 2005;102(50):18034–18039. doi:10.1073/pnas.050910910216332960
   PubMed Web of Science ®Google Scholar
• Manderfield LJ, Engleka KA, Aghajanian H, et al. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest. Cell Rep. 2014;9(5):1885–1895. doi:10.1016/j.celrep.2014.10.06125466249
   PubMed Web of Science ®Google Scholar
• Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138(1):9–22. doi:10.1242/dev.04550021138973
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24(9):862–874. doi:10.1101/gad.190921020439427
   PubMed Web of Science ®Google Scholar
• Kim M, Kim T, Johnson RL, Lim DS. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Cell Rep. 2015;11(2):270–282. doi:10.1016/j.celrep.2015.03.01525843714
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–257. doi:10.1038/nrc345823467301
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780–791. doi:10.1016/j.cell.2012.06.03722863277
   PubMed Web of Science ®Google Scholar
• Webb C, Upadhyay A, Giuntini F, et al. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway. Biochemistry. 2011;50(16):3300–3309. doi:10.1021/bi200188821417403
   PubMed Web of Science ®Google Scholar
• Ernst A, Appleton BA, Ivarsson Y, et al. A structural portrait of the PDZ domain family. J Mol Biol. 2014;426(21):3509–3519. doi:10.1016/j.jmb.2014.08.01225158098
   PubMed Web of Science ®Google Scholar
• Schlegelmilch K, Mohseni M, Kirak O, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell. 2011;144(5):782–795. doi:10.1016/j.cell.2011.02.03121376238
   PubMed Web of Science ®Google Scholar
• Xu CM, Liu WW, Liu CJ, Wen C, Lu HF, Wan FS. Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo. Cancer Gene Ther. 2013;20(8):453–460. doi:10.1038/cgt.2013.4023928732
   PubMed Web of Science ®Google Scholar
• Bai H, Zhang N, Xu Y, et al. Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology. 2012;56(3):1097–1107. doi:10.1002/hep.2576922886419
   PubMed Web of Science ®Google Scholar
• Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5(4):1060–1069. doi:10.1016/j.celrep.2013.10.03024268772
   PubMed Web of Science ®Google Scholar
• Zhang W, Cohen SM. The Hippo pathway acts via p53 and microRNAs to control proliferation and proapoptotic gene expression during tissue growth. Biol Open. 2013;2(8):822–828. doi:10.1242/bio.2013431723951408
   PubMed Web of Science ®Google Scholar
• Bai H, Gayyed MF, Lam-Himlin DM, et al. Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies. Hum Pathol. 2012;43(9):1376–1385. doi:10.1016/j.humpath.2011.12.00122436626
   PubMed Web of Science ®Google Scholar
• Barry ER, Morikawa T, Butler BL, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493(7430):106–110. doi:10.1038/nature1169323178811
   PubMed Web of Science ®Google Scholar
• Fujii M, Toyoda T, Nakanishi H, et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209(3):479–494. doi:10.1084/jem.2011165322329991
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhang Y, Wu H, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A. 2011;108(49):E1312–E1320. doi:10.1073/pnas.111042810822042863
   PubMed Web of Science ®Google Scholar
• Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17(23):2054–2060. doi:10.1016/j.cub.2007.10.03917980593
   PubMed Web of Science ®Google Scholar
• Heinemann A, Cullinane C, De Paoli-Iseppi R, et al. HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget. 2015;6(25):21507–21521. doi:10.18632/oncotarget.424226087189
   PubMedGoogle Scholar
• Lin Z, Zhou P, von Gise A, et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ Res. 2015;116(1):35–45. doi:10.1161/CIRCRESAHA.115.30445725249570
   PubMed Web of Science ®Google Scholar
• Lau AN, Curtis SJ, Fillmore CM, et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. Embo J. 2014;33(5):468–481. doi:10.1002/embj.20138608224497554
   PubMed Web of Science ®Google Scholar
• Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–1096. doi:10.1016/j.jhep.2014.06.03325010260
   PubMed Web of Science ®Google Scholar
• Xia Y, Chang T, Wang Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014;9(3):e91770. doi:10.1371/journal.pone.009177024622501
   PubMed Web of Science ®Google Scholar
• Wu Q, Li J, Sun S, et al. YAP/TAZ-mediated activation of serine metabolism and methylation regulation is critical for LKB1-deficient breast cancer progression. Biosci Rep. 2017;37(5):BSR20171072. doi:10.1042/BSR2017107228931725
   PubMedGoogle Scholar
• Zhou GX, Li XY, Zhang Q, et al. Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev. 2013;14(9):5199–5205.24175801
   PubMedGoogle Scholar
• Wang Y, Xie C, Li Q, Xu K, Wang E. Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol. 2013;34(4):2169–2174. doi:10.1007/s13277-013-0751-x23558963
   PubMedGoogle Scholar
• Debaugnies M, Sanchez-Danes A, Rorive S, et al. YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep. 2018;19:7. doi:10.15252/embr.201845809
   Web of Science ®Google Scholar
• Maglic D, Schlegelmilch K, Dost AF, et al. YAP-TEAD signaling promotes basal cell carcinoma development via a c-JUN/AP1 axis. Embo J. 2018;37:17. doi:10.15252/embj.201798642
   Web of Science ®Google Scholar
• Akladios B, Mendoza Reinoso V, Cain JE, et al. Positive regulatory interactions between YAP and Hedgehog signalling in skin homeostasis and BCC development in mouse skin in vivo. PLoS One. 2017;12(8):e0183178. doi:10.1371/journal.pone.018317828820907
   PubMed Web of Science ®Google Scholar
• Quan T, Xu Y, Qin Z, et al. Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: impact on keratinocyte proliferation and stromal cell activation. Am J Pathol. 2014;184(4):937–943. doi:10.1016/j.ajpath.2013.12.01724485923
   PubMed Web of Science ®Google Scholar
• Guo P, Kang S, Zhao F. High expression of TAZ/YAP promotes the progression of malignant melanoma and affects the postoperative survival of patients. Pharmazie. 2018;73(11):662–665. doi:10.1691/ph.2018.849930396386
   PubMed Web of Science ®Google Scholar
• Xiong H, Yu Q, Gong Y, et al. Yes-Associated Protein (YAP) promotes tumorigenesis in melanoma cells through stimulation of low-density Lipoprotein Receptor-Related Protein 1 (LRP1). Sci Rep. 2017;7(1):15528. doi:10.1038/s41598-017-14764-429138479
   PubMedGoogle Scholar
• Kim MH, Kim CG, Kim SK, et al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 2018. doi:10.1158/2326-6066.CIR-17-0320
   Web of Science ®Google Scholar
• Sambandam SAT, Kasetti RB, Xue L, Dean DC, Lu Q, Li Q. 14-3-3sigma regulates keratinocyte proliferation and differentiation by modulating Yap1 cellular localization. J Invest Dermatol. 2015;135(6):1621–1628. doi:10.1038/jid.2015.4225668240
   PubMed Web of Science ®Google Scholar
• Elbediwy A, Vincent-Mistiaen ZI, Spencer-Dene B, et al. Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development. 2016;143(10):1674–1687. doi:10.1242/dev.13372826989177
   PubMed Web of Science ®Google Scholar
• Jia J, Li C, Luo S, et al. Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of RAS. J Invest Dermatol. 2016;136(6):1267–1277. doi:10.1016/j.jid.2016.02.00526902922
   PubMed Web of Science ®Google Scholar
• Li Y, Kong F, Wang J, et al. S100A7 induction is repressed by YAP via the Hippo pathway in A431 cells. Oncotarget. 2016;7(25):38133–38142. doi:10.18632/oncotarget.947727203549
   PubMedGoogle Scholar
• Li Y, Kong F, Shao Q, et al. Activity are suppressed by S100A7 via p65/NFkappaB-mediated repression of DeltaNp63. Mol Cancer Res. 2017;15(12):1752–1763. doi:10.1158/1541-7786.MCR-17-034928923839
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Yamana H. [Molecular biology for esophageal squamous cell carcinoma]. Nihon Rinsho. 2011;69(Suppl 6):51–56.
   PubMedGoogle Scholar
• Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 2011;32(3):389–398. doi:10.1093/carcin/bgq25421112960
   PubMed Web of Science ®Google Scholar
• Yeo MK, Kim SH, Kim JM, et al. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Anticancer Res. 2012;32(9):3835–3840.22993326
   PubMed Web of Science ®Google Scholar
• Ge L, Smail M, Meng W, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One. 2011;6(11):e27529. doi:10.1371/journal.pone.002752922096589
   PubMed Web of Science ®Google Scholar
• Saladi SV, Ross K, Karaayvaz M, et al. ACTL6A is co-amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 2017;31(1):35–49. doi:10.1016/j.ccell.2016.12.00128041841
   PubMed Web of Science ®Google Scholar
• Wang Y, Gersten A, Moleirinho S, Gunn-Moore FJ, Reynolds PA, Prystowsky MB. Fibroblasts in head and neck squamous cell carcinoma associated with perineural invasion have high-level nuclear Yes-Associated Protein (YAP) Expression. Acad Pathol. 2015;2(4):2374289515616972. doi:10.1177/237428951561697228725753
   PubMedGoogle Scholar
• Verduci L, Ferraiuolo M, Sacconi A, et al. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol. 2017;18(1):237. doi:10.1186/s13059-017-1368-y29262850
   PubMed Web of Science ®Google Scholar
• Snijders AM, Schmidt BL, Fridlyand J, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24(26):4232–4242. doi:10.1038/sj.onc.120860115824737
   PubMed Web of Science ®Google Scholar
• Hiemer SE, Zhang L, Kartha VK, et al. A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. Mol Cancer Res. 2015;13(6):957–968. doi:10.1158/1541-7786.MCR-14-058025794680
   PubMed Web of Science ®Google Scholar
• Chen X, Gu W, Wang Q, et al. C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC. Oncotarget. 2018;9(1):668–679. doi:10.18632/oncotarget.2308929416644
   PubMedGoogle Scholar
• Wei Z, Wang Y, Li Z, et al. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients’ prognosis. Int J Stomatol Occlusion Med. 2013;42(10):747–754. doi:10.1111/jop.12062
   Google Scholar
• Silverberg SG, Ioffe OB. Pathology of cervical cancer. Cancer J. 2003;9(5):335–347.14690308
   PubMed Web of Science ®Google Scholar
• Liu T, Liu Y, Gao H, Meng F, Yang S, Lou G. Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. Int J Gynecol Cancer. 2013;23(4):735–742. doi:10.1097/IGC.0b013e31828c861923502453
   PubMed Web of Science ®Google Scholar
• Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–1305. doi:10.1101/gad.192856.11222677547
   PubMed Web of Science ®Google Scholar
• Brodowska K, Al-Moujahed A, Marmalidou A, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014;124:67–73. doi:10.1016/j.exer.2014.04.01124837142
   PubMed Web of Science ®Google Scholar
• Wang C, Zhu X, Feng W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3sigma sequestering YAP in the cytoplasm. Am J Cancer Res. 2016;6(1):27–37.27073720
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang Z, Huang W, Lei QY. G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway. Acta Biochim Biophys Sin (Shanghai). 2015;47(1):10–15. doi:10.1093/abbs/gmu10825491506
   PubMed Web of Science ®Google Scholar
• Liu G, Yu FX, Kim YC, et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene. 2015;34(27):3536–3546. doi:10.1038/onc.2014.28125195862
   PubMed Web of Science ®Google Scholar
• Hsu YL, Hung JY, Chou SH, et al. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene. 2015;34(31):4056–4068. doi:10.1038/onc.2014.33325381822
   PubMed Web of Science ®Google Scholar
• Kang W, Huang T, Zhou Y, et al. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis. 2018;9(2):92. doi:10.1038/s41419-017-0134-029367737
   PubMed Web of Science ®Google Scholar